Tech Company Financing Transactions
Avistone Biotechnology Funding Round
Avistone Biotechnology closed a $140 million Series B financing round on 1/4/2024. Investors included IDG Capital Partners, SDIC Fund Management and Bain Capital Ventures.
Transaction Overview
Company Name
Announced On
1/4/2024
Transaction Type
Venture Equity
Amount
$140,000,000
Round
Series B
Investors
IDG Capital Partners (Lead Investor)
SDIC Fund Management (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support clinical research and development of its pipeline, including both drug monotherapy studies and internal combinations, to accelerate the screening of new molecules, to support clinical studies and expansion in the United States of America, and to support commercialization of PLB1001 (Vebreltinib) in China.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5th Floor, Block B, Wangjing Science and Technology Park, Li
Beijing, Undisclosed
China
Beijing, Undisclosed
China
Phone
Website
Email Address
Overview
Our Company is focused on health services industry, aiming to offer high-quality medical products to patients. Our main areas of research are "best in class" and "first in class" innovative drugs, principally for the treatment of tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shi Hepeng
Chief Technical Officer
Zhang Peilong
Vice President
Kevin Schaab
VP - Bus. Development
David Chung
Browse more venture capital transactions:
Prev: 1/4/2024: Knownwell venture capital transaction
Next: 1/4/2024: MaximBio venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs